Health Catalyst, Inc. (NASDAQ:HCAT) COO Daniel Lesueur Sells 5,209 Shares

Health Catalyst, Inc. (NASDAQ:HCAT) COO Daniel Lesueur sold 5,209 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $7.51, for a total transaction of $39,119.59. Following the sale, the chief operating officer now directly owns 91,253 shares of the company’s stock, valued at $685,310.03. This represents a 5.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Daniel Lesueur also recently made the following trade(s):

• On Tuesday, November 5th, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The shares were sold at an average price of $7.70, for a total transaction of $40,109.30.

Health Catalyst Price Performance

HCAT opened at $6.89 on Friday. The company has a 50-day moving average of $7.79 and a 200-day moving average of $7.52. The company has a market capitalization of $419.24 million, a P/E ratio of -5.10 and a beta of 1.36. Health Catalyst, Inc. has a 1-year low of $5.42 and a 1-year high of $11.41. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41.

Health Catalyst (NASDAQ:HCAT) last released its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). The company had revenue of $76.40 million during the quarter, compared to the consensus estimate of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. Health Catalyst’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.22) EPS. Equities analysts expect that Health Catalyst, Inc. will post -0.33 EPS for the current fiscal year.

Institutional Investors Weigh In On Health Catalyst

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Primecap Management Co. CA grew its position in shares of Health Catalyst by 14.7% during the 2nd quarter. Primecap Management Co. CA now owns 2,379,462 shares of the company’s stock valued at $15,205,000 after buying an additional 305,079 shares during the last quarter. Janney Montgomery Scott LLC bought a new stake in shares of Health Catalyst during the 3rd quarter valued at about $897,000. Fred Alger Management LLC bought a new stake in shares of Health Catalyst during the 3rd quarter valued at about $6,858,000. Millrace Asset Group Inc. bought a new stake in shares of Health Catalyst during the 3rd quarter valued at about $1,568,000. Finally, Point72 Asset Management L.P. grew its position in shares of Health Catalyst by 69.4% during the 3rd quarter. Point72 Asset Management L.P. now owns 516,934 shares of the company’s stock valued at $4,208,000 after buying an additional 211,805 shares during the last quarter. Institutional investors own 85.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on HCAT. Cantor Fitzgerald restated an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a report on Friday, October 4th. Evercore ISI lifted their target price on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. KeyCorp upgraded shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price on the stock in a report on Wednesday. Stephens lifted their target price on shares of Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a report on Thursday, November 14th. Finally, Piper Sandler restated an “overweight” rating and set a $12.00 target price (up previously from $11.00) on shares of Health Catalyst in a report on Tuesday, November 26th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $11.45.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.